Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
Year: 2017
Type: review
Abstract: Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach that aims to induce production of partially functional dystrophins. Recently, an AON targeting exon 51 became the first of its class to be approved by the United States regulators [Food and Drug Administration (FDA)] for the treatment of DMD. A unique aspect of the exon-skipping approach for DMD is that, depending on the size and location of the mutation, different exons need to be skipped. This challenge raises a number of questions regarding the development and regulatory approval of those individual compounds. In this study, we present a perspective on those questions, following a European stakeholder meeting involving academics, regulators, and representatives from industry and patient organizations, and in the light of the most recent scientific and regulatory experience.
Source: Nucleic Acid Therapeutics
Institutions: Leiden University Medical Center, Newcastle University, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, Federal Institute for Drugs and Medical Devices, Medicines Evaluation Board, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Centro Clinico Nemo, University College London, University of Lisbon
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: Pfizer, Biogen, BioClinica, Ultragenyx Pharmaceutical, PTC Therapeutics, Ionis Pharmaceuticals, AveXis, Sarepta Therapeutics, Audentes Therapeutics, National Institute for Health and Care Research, Great Ormond Street Hospital for Children, Leids Universitair Medisch Centrum, ProQR Therapeutics, Italfarmaco, Sanofi Genzyme
OpenAlex ID: W2743090929
